# Lumexa Imaging Holdings Inc. (LMRI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.18, market value $1.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Lumexa Imaging Holdings Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.26**. A PEG of 0.26 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.2×**. Each dollar of revenue is priced at 1.2×.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 15.5×**. Enterprise value is 15.5× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 0.3%** (5-yr avg -0.5%). Free cash flow equals 0.3% of the market value, above its five-year average of -0.5%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Operating margin: 9.4%**. 9.4% of revenue is left after running the business.
- **Net margin: -4.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -8.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 5.1%**. Return on all capital, debt included, is 5.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -0.6%**. Each dollar of assets produces -0.6% of profit.

## Growth
- **Revenue growth (1 yr): 7.8%**. Revenue grew 7.8% over the last year.
- **EPS growth (1 yr): 51.1%**. Earnings per share rose 51.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.64**. Debt is 1.64 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 6.7×**. It would take 6.7 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 1.27** (quick 1.27). Current assets cover the next year's liabilities 1.27 times.
- **Altman Z-score: 1.72**. A Z-score of 1.72 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Lumexa Imaging Holdings Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (7 analysts). 7 analysts cover Lumexa Imaging Holdings Inc.; the consensus is strong_buy, with an average price target of $17.57 (+44% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -37.4%** (88.8% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.68** (volatility 81%). Beta of 1.68 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LMRI · Page: https://foliofundamentals.com/stocks/lmri

Not investment advice.